12 Oversold Global Stocks to Invest In

Page 3 of 10

8. Arcellx, Inc. (NASDAQ:ACLX)

Share Price Decline Versus 52-Week High: 24.27%

Relative Strength Index: 28.79

Upside Potential: 54.96%

Arcellx, Inc. (NASDAQ:ACLX) is included in our list of the 12 oversold global stocks to invest in.

On November 25, 2025, Arcellx, Inc. (NASDAQ:ACLX) saw Morgan Stanley’s Judah Frommer reiterate a “Buy” rating. The investment firm’s bullish stance stemmed from the company’s CAR-T therapy’s safety profile, potential for high minimal residual disease (MRD) negativity rates, and differentiation from existing treatments like Carvykti. The analyst noted that the therapy, aimed at treating multiple myeloma (MM), remains a key growth driver for the company.

Management remains confident that CAR-T therapy will capture a substantial share of the 2L-3L global MM market, particularly within large healthcare enterprises and academic centers. Moreover, the analyst highlighted the upcoming data presentations at the ASH meeting, which are expected to provide further validation for anito-cel’s durability and efficacy. Together, these factors are expected to drive upside in the stock.

Meanwhile, on November 5, 2025, Arcellx, Inc. (NASDAQ:ACLX) reported its Q3 2025 results. The company closed the quarter with $576 million in cash, providing a runway into 2028. Due to completion of dosing in the iMMagine-1 trial, collaboration revenue fell from $26 million in Q3 2024 to $4.9 million. Net loss for the quarter was $55.8 million, widening from $25.9 million in Q3 2024.

Arcellx, Inc. (NASDAQ:ACLX) is focused on the development of innovative CAR-T and cell therapies for cancer and incurable diseases.

Page 3 of 10